ロード中...
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials
Several randomized clinical trials have suggested the effectiveness of bevacizumab (Bev) in early and advanced breast cancer; however, due to the increased toxicity and lack of a clear long-term survival benefit, there is currently no defined role for Bev in breast cancer in the USA, while it has be...
保存先:
| 出版年: | Mol Clin Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6388502/ https://ncbi.nlm.nih.gov/pubmed/30847174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2019.1796 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|